Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population

被引:180
作者
Gaikovitch, EA
Cascorbi, I
Mrozikiewicz, PM
Brockmöller, J
Frötschl, R
Köpke, K
Gerloff, T
Chernov, JN
Roots, I
机构
[1] Humboldt Univ, Inst Clin Pharmacol, Univ Clin Charite, D-10098 Berlin, Germany
[2] Voronezh State Med Acad, Dept Clin Pharmacol, Voronezh, Russia
[3] Ernst Moritz Arndt Univ Greifswald, Inst Pharmacol, Greifswald, Germany
[4] Univ Gottingen, Dept Clin Pharmacol, D-3400 Gottingen, Germany
关键词
cytochrome P-450; CYP; NAT2; MDR1; Russians; haplotypes;
D O I
10.1007/s00228-003-0606-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective. The frequency of functionally important mutations and alleles of genes coding for xenobiotic metabolizing enzymes shows a wide ethnic variation. However, little is known of the frequency distribution of the major allelic variants in the Russian population. Methods. Using polymerase chain reaction/restriction fragment length polymorphism (PCR/RFLP) genotyping assays and the real-time PCR with fluorescent probes, the frequencies of functionally important variants of the cytochromes P-450 (CYP) 2C9, 2C19, 2D6, 1A1 as well as arylamine N-acetyltransferase 2 (NAT2) and P-glycoprotein (MDR1) were determined in a sample of 290 Russian volunteers derived from Voronezh area. Results. CYP2C9*2 and *3 alleles were found with allelic frequencies of 10.5% and 6.7%, respectively. The novel intron-2 T>C mutation at exon 2 +73 bp occurred in 24.8% of alleles. CYP2C19*2 and *3 alleles occurred in 11.4% and 0.3%, respectively. Six persons (2.1%) carried two of these CYP2C19 alleles responsible for poor metabolizing activity. Of all subjects, 5.9% were CYP2D6 poor metabolizers, whereas 3.4% were addressed to ultra-rapid metabolizers (CYP2D6*1x2/*1). The CYP1A1*2A allele was found in 4.7%, *2B in 5.0%, *4 in 2.6%, and the 5'-mutations -3219C>T, -3229G>A, and the novel -4335G>A in 6.0%, 2.9% and 26.0% of alleles, respectively. Genotyping of eight different single nucleotide polymorphisms in the NAT2 gene provided in 58.0% a genotype associated with slow acetylation. The MDR1 triple variants G2677T and G2677A in exon 21 had an allelic frequency of 41.9% and 3.3%, respectively, and the variant C3435T in exon 26 one of 54.3%. Frequencies of functionally important haplotypes were calculated. Conclusion. The overview of allele distribution of important xenobiotic-metabolizing enzymes among a Russian population shows similarity to other Caucasians. The data will be useful for clinical pharmacokinetic investigations and for drug dosage recommendations in the Russian population.
引用
收藏
页码:303 / 312
页数:10
相关论文
共 51 条
[1]   Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].
Aithal, GP ;
Day, CP ;
Kesteven, PJL ;
Daly, AK .
LANCET, 1999, 353 (9154) :717-719
[2]  
Aklillu E, 1996, J PHARMACOL EXP THER, V278, P441
[3]   MDR1 pharmacogenetics:: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity [J].
Ameyaw, MM ;
Regateiro, F ;
Li, T ;
Liu, XH ;
Tariq, M ;
Mobarek, A ;
Thornton, N ;
Folayan, GO ;
Githang'a, J ;
Indalo, A ;
Ofori-Adjei, D ;
Price-Evans, DA ;
McLeod, HL .
PHARMACOGENETICS, 2001, 11 (03) :217-221
[4]  
Aynacioglu AS, 1999, BRIT J CLIN PHARMACO, V48, P409
[5]   Arylamine N-acetyltransferase (NAT2) genotypes in a Turkish population [J].
Aynacioglu, AS ;
Cascorbi, I ;
Mrozikiewicz, PM ;
Roots, I .
PHARMACOGENETICS, 1997, 7 (04) :327-331
[6]   Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population [J].
Aynacioglu, AS ;
Sachse, C ;
Bozkurt, A ;
Kortunay, S ;
Nacak, M ;
Schröder, T ;
Kayaalp, SO ;
Roots, I ;
Brockmöller, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (02) :185-192
[7]   Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population [J].
Bathum, L ;
Skjelbo, E ;
Mutabingwa, TK ;
Madsen, H ;
Horder, M ;
Brosen, K .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 48 (03) :395-401
[8]   Identification of N-acetyltransferase 2 genotypes by continuous monitoring of fluorogenic hybridization probes [J].
Blömeke, B ;
Sieben, S ;
Spötter, D ;
Landt, O ;
Merk, HF .
ANALYTICAL BIOCHEMISTRY, 1999, 275 (01) :93-97
[9]  
Borlak J, 2002, CLIN CHEM, V48, P1592
[10]   Arylamine N-acetyltransferase activity in man [J].
Cascorbi, I ;
Brockmöller, J ;
Mrozikiewicz, PM ;
Müller, A ;
Roots, I .
DRUG METABOLISM REVIEWS, 1999, 31 (02) :489-502